| September 2018 | Product Launch | Medtronic launched the Infinity (TM) Occipitocervical-Upper Thoracic (OCT) System. This product was designed to simplify the posterior cervical spine surgery. |
| – | Product Launch | The company launched Infinity OCT Spinal System. |
| – | Product Approval | The company received premarket approval for the Deep Brain Stimulation (DBS) therapy as the adjunctive treatment for Epilepsy. |
| – | Product Approval | The company received CE approvals for the Intellis platform for Spinal Cord Stimulation (SCS). |
| – | Product Approval | The company received FDA approvals and launched the Intellis platform, SCS for the management of chronic pain. |
| – | Product Approval | The company received CE approvals for SureTune3 software for deep brain stimulation (DBS) therapy. |
| – | Product Approval | The company received the Health Canada License for SureTune3 software for deep brain stimulation (DBS) therapy. |
| – | Product Approval | The company received CE approvals for the SureTune2 software for the deep brain stimulation therapy. |
| – | Expansion | The company opened Asia-Pacific regional headquarters in Singapore. |
| – | Product Approval | FDA approved Medtronic’s Deep Brain Stimulation therapy for Parkinson's disease. |
| – | Acquisition | The company acquired Sapiens SBS (Netherlands). This acquisition strengthens its deep brain stimulation therapy product portfolio. |
| December 2018 | Acquisition | Medtronic PLC announced the acquisition of Israel-based Mazor Robotics. This will strengthen the company’s position as a global innovator in enabling technologies for spine surgery. |
| September 2017 | Product Launch | Medtronic launched StealthStation ENT. This product was designed for surgeons treating conditions within the ear, nose, and throat (ENT) anatomy. This will improve the company’s ENT product portfolio. |
| April 2017 | Product Launch | Medtronic PLC announced the launch of the StealthStation(TM) technology at the American Academy of Neurological Surgeons (AANS) annual conference in Los Angeles. The product was an advanced solution to neurosurgeons. |
| September 2016 | FDA Approval | The company announced the US Food and Drug Administration (FDA) clearance of StealthStation Cranial Software as an aid for deep brain stimulation (DBS) lead placement. This will help the company to provide a complete procedural solution for the planning and placement of DBS leads. |
| May 2016 | Expansion | The company announced the opening of its new Asia-Pacific headquarters in Singapore. This will help the company to strengthen and support Medtronic operations across 80 locations in Asia-Pacific |
| March 2017 | Approval | Medtronic announced the US FDA approval for its “Reveal LINQ Insertable Cardiac Monitor” with TruRhythm Detection, an improved cardiac monitor. This device will help patients to monitor their heartbeat for up to three years wirelessly. This approval will increase the product portfolio of the company. |
| September 2016 | Approval | Medtronic announced that the Ministry of Health, Labor, and Welfare (MHLW) approved the Reveal LINQ Insertable Cardiac Monitor system in Japan. This approval will aid a lot of Japanese patients experiencing syncope and strokes. The device detects and records abnormal heart rhythms for up to three years. This approval will help the company to penetrate the Japanese market. |
| – | Acquisition | Medtronic acquired Covidien plc, a public limited company which helped Medtronic to reach more customers and tap new market |
| – | Acquisition | Medtronic completed the acquisition of HeartWare International, Inc., a leading innovator of less-invasive, miniaturized, mechanical circulatory support technologies (MCS) for treating patients with advanced heart failure. |
| Sep-2019 | Product Launch | Medtronic announced the launch of the AccuGuide Steerable Biopsy System, a new biopsy solution designed to provide physicians with enhanced access and control during breast biopsy procedures. |
| Oct-2019 | Collaboration | Medtronic announced a collaboration with Mercy Health to develop new value-based care models for the treatment of several medical conditions, including breast cancer. |
| Jan-2020 | Acquisition | Medtronic announced the acquisition of Stimgenics, a company that develops a novel spinal cord stimulation (SCS) therapy for treating chronic pain. While not directly related to breast biopsy, the acquisition demonstrates Medtronic's ongoing commitment to investing in new medical technologies. |
| May-2021 | Product Launch | Medtronic announced the launch of the AccuPunch Robotic Biopsy System, a new robotic-assisted biopsy solution designed to provide physicians with greater accuracy and efficiency during breast biopsy procedures. |
| Sep-2021 | Acquisition | Medtronic announced the acquisition of AKTORmed, a company that develops orthopedic surgical technologies. While not directly related to breast biopsy, the acquisition demonstrates Medtronic's ongoing focus on expanding its product offerings and entering new therapeutic areas. |